Your browser doesn't support javascript.
loading
Complete Response to R-EPOCH in Primary Cardiac Lymphoma.
Anand, Kartik; Pingali, Sai Ravi; Trachtenberg, Barry; Iyer, Swaminathan Padmanabhan.
Afiliación
  • Anand K; Houston Methodist Cancer Center, Weill Cornell Medicine, Houston, TX, USA.
  • Pingali SR; Houston Methodist Cancer Center, Weill Cornell Medicine, Houston, TX, USA.
  • Trachtenberg B; Division of Cardiology, DeBakey Heart & Vascular Institute, Houston Methodist Hospital, Houston, TX, USA.
  • Iyer SP; Houston Methodist Cancer Center, Weill Cornell Medicine, Houston, TX, USA.
Case Rep Hematol ; 2019: 7690430, 2019.
Article en En | MEDLINE | ID: mdl-31214365
Primary cardiac lymphoma (PCL) is a rare extranodal lymphoma involving only the heart and/or the pericardium. Most common presenting signs and symptoms are nonspecific including dyspnea, pericardial effusion, and arrhythmia. Prognosis of PCL patients remain poor compared to non-cardiac lymphoma patients. Since most of the information about PCL comes from case reports or case series, there is no treatment consensus. Anthracycline containing chemotherapy remains main treatment modality which is potentially cardiotoxic. We present a case of PCL that achieved complete remission using R-EPOCH (rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin). We also used dexrazoxane in an effort to reduce cardiotoxicity of chemotherapy.

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Case Rep Hematol Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Case Rep Hematol Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos
...